Overview Request Sample Pages Request Customization Download PDF
You are viewing: Japan Protein Expression Market analysis
Part of: Protein Expression Market (Global)

The Japan Protein Expression Market was valued at $212.6 Million in 2026 and projected to reach to $330.1 Million by 2031, representing a compound annual growth rate of 9.2%. Japan's protein expression market is poised for sustained expansion through 2031, driven by increasing investments in biopharmaceutical development and growing demand for therapeutic protein production.

Japan Protein Expression Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Protein Expression Market Trends and Insights

  • Japan's advanced biotechnology infrastructure and strong pharmaceutical R&D investments are driving demand for protein expression technologies across research institutions and biopharmaceutical companies.
  • The market in Japan benefits from the country's leadership in precision medicine and growing adoption of recombinant protein production systems. The 9.2% compound annual growth rate in Japan outpaces the global average, reflecting increased investment in biologics development and therapeutic protein manufacturing.
  • Japan's protein expression market is supported by government initiatives promoting life sciences innovation and the presence of major biotech hubs.
  • Between 2026 and 2031, Japan is expected to see accelerated adoption of cell-free and mammalian expression systems, driven by demand for complex protein therapeutics and vaccine development platforms..

Key Market Statistics

  • CAGR (2026-2031) 9.2% CAGR
  • Market Size, 2026 ~USD 212.6 Million
  • Forecast, 2031 ~USD 330.1 Million
  • Country Japan

Japan Protein Expression Market Overview

Market Valuation Growth :

Japan's protein expression market is valued at USD 212.6 million in 2026 and is projected to reach USD 330.1 million by 2031, representing a robust 9.2% CAGR, outpacing the global average of 8.3%.

Advanced Biotechnology Infrastructure :

Japan possesses world-class research facilities and biotechnology hubs, particularly in Tokyo, Osaka, and Kyoto, supporting accelerated adoption of protein expression technologies among academic and commercial entities.

Pharmaceutical R&D Investment :

Strong government and private sector investments in pharmaceutical research and development are driving demand for protein expression solutions across Japanese biopharmaceutical companies and contract research organizations.

Regional Innovation Leadership :

Japan's commitment to precision medicine and regenerative biology research positions it as a key market for cutting-edge protein expression platforms and recombinant protein production technologies.

Japan Protein Expression Market Dynamics

  • The country's aging population and focus on advanced healthcare solutions are accelerating adoption of protein expression technologies in drug discovery and development pipelines.
  • Japanese pharmaceutical companies are increasingly leveraging protein expression systems for monoclonal antibody production and personalized medicine applications, creating significant growth opportunities. The market will benefit from collaborations between Japanese research institutions and global biotech firms, as well as government initiatives supporting life sciences innovation.
  • Technological advancements in expression systems, coupled with rising demand for biosimilars and biologics, will further propel market growth.
  • Japan's regulatory framework and quality standards continue to attract international investment, positioning the country as a critical hub for protein expression research and manufacturing in the Asia-Pacific region..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Japan's protein expression market will grow from USD 212.6M (2026) to USD 330.1M (2031) at a 9.2% CAGR, outpacing global growth rates.
    • Japan's advanced biotech infrastructure and government support for life sciences innovation are primary drivers of market expansion.
    • Increased demand for recombinant proteins and therapeutic biologics in Japan is accelerating adoption of mammalian and cell-free expression systems.
    • Japan's protein expression market is positioned as a key regional hub for biologics manufacturing and precision medicine development through 2031.

    Protein Expression Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment SOFTWARE (Type)
    Forecast Period 2026–2031
    Growth Rate CAGR of 8.3% from 2026 to 2031
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 5.13 (2026)
    Revenue Forecast (Billions) ~USD 7.65 (2031)
    Segments Covered Offering, Type, End User, Workflow, Scale Of Operation, Protein Modality, Application

    Japan Protein Expression Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services

    By Type

    • Algal & Plant-Based Expression Systems
    • Algal-Based Expression Systems
    • Analytical Instruments
    • Bacillus Systems
    • Baculovirus Systems
    • Bioreactors & Fermenters
    • Cell-Free Expression Systems
    • Cho Cell Systems
    • Chromatography & Purification Consumables
    • Chromatography Systems
    • Cld Services
    • Cloning & Mutagenesis Kits
    • Competent Cells
    • Consumables
    • Culture Media & Supplements
    • Custom Protein Expression Services
    • E. Coli Lysate-Based Systems
    • E. Coli Systems
    • Expression Kits
    • Expression Vectors & Plasmids
    • Filtration & Separation Consumables
    • Filtration Systems
    • Gene Synthesis & Cloning Services
    • Hek 293 Cell Systems
    • Insect Cell Expression Systems
    • Instruments
    • Kits
    • Liquid Handling & Automation Systems
    • Mammalian Cell Expression Systems
    • Other Cell-Free Expression Systems
    • Other Consumables
    • Other Insect Cell Expression Systems
    • Other Instruments
    • Other Kits
    • Other Mammalian Cell Expression Systems
    • Other Prokaryotic Expression Systems
    • Other Reagents
    • Other Yeast Expression Systems
    • Pichia Systems
    • Process Development & Scale-Up Services
    • Prokaryotic Expression Systems
    • Reagents
    • Saccharomyces Systems
    • Software
    • Transduction & Transfection Reagents
    • Yeast Expression Systems

    By End User

    • Academic & Research Institutes
    • Cros & Cdmos
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    By Workflow

    • Cloning & Transfection
    • Extraction, Purification, And Characterization
    • Transcription, Translation, And Post-Translational Modification (Ptm)

    By Scale Of Operation

    • Discovery & Research Scale
    • Preclinical & Characterization Scale
    • Process Development & Pilot Scale

    By Protein Modality

    • Enzymes & Catalytic Proteins
    • Monoclonal Antibodies & Derivatives
    • Other Proteins
    • Recombinant Therapeutic Proteins
    • Vaccines

    By Application

    • Diagnostic Applications
    • Industrial Applications
    • Research Applications
    • Therapeutic Applications

    JAPAN: PROTEIN EXPRESSION SERVICES MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES12.613.314.916.317.919.721.623.79.8
    OTHER END USERS3.63.744.44.755.45.87.6
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES23.9252830.733.536.840.2449.5
    TOTAL40.141.946.951.356.261.567.373.59.4

    JAPAN: PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES41.343.348.553.358.464.170.3779.7
    CROS & CDMOS46.849.255.360.96773.7818910
    OTHER END USERS35.436.540.243.346.750.354.258.27.7
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES59.161.668.67581.789.297.2105.99.1
    TOTAL182.6190.6212.6232.5253.8277.3302.7330.19.2

    Target Audience

    • Biopharmaceutical Companies : Japanese and international biotech firms need market intelligence to guide R&D investments, manufacturing decisions, and commercial strategies for protein expression-based therapeutics in Japan's growing market.
    • Contract Research Organizations (CROs) : CROs operating in Japan require detailed market data to identify service expansion opportunities, benchmark capabilities against competitors, and align offerings with evolving customer demands in protein expression services.
    • Research Institutions and Universities : Japanese academic and research centers need market insights to secure funding, collaborate with industry partners, and align research programs with commercial applications in protein expression technology.
    • Equipment and Technology Vendors : Manufacturers of protein expression systems, bioreactors, and analytical instruments need Japan-specific market data to identify customer segments, forecast demand, and develop localized product strategies.
    • Investment and Private Equity Firms : Investors targeting Japan's life sciences sector require comprehensive market analysis to evaluate investment opportunities, assess portfolio company growth potential, and identify emerging players in protein expression.

    Key Companies in the Japan Protein Expression Market

    CompanyHQOwnershipStrongest segments
    PATHEON INCNetherlandsPrivate CompanyDrug Product Services (finished dosage manufacturing & packaging),Pharmaceutical Development Services,Drug Substance Services (small- and large-molecule APIs),
    NANOSTRING TECHNOLOGIES, INCUnited StatesPrivate CompanynCounter instruments and consumables (Pro, FLEX, SPRINT, CodeSets, panels, reagents),GeoMx DSP and spatial biology solutions,Prosigna and other in vitro diagnostic kits,
    BIOGENUnited StatesPublic CompanyMultiple Sclerosis therapies (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SPINRAZA and rare neuromuscular (SPINRAZA, QALSODY, SKYCLARYS),Alzheimer’s and neuropsychiatry (LEQEMBI, ZURZUVAE),
    SIGMA-ALDRICH CORPORATIONUnited StatesPrivate CompanyPharma and biopharma manufacturing (media, filtration, critical raw materials, safety testing),Research reagents and molecular biology (chemicals, biochemicals, functional genomics, protein biology),Analytical chemistry, diagnostics, and industrial microbiology,
    VIVA BIOTECH LTDChinaPublic CompanyDiscovery biology & structural biology services,Medicinal and synthetic chemistry & CADD,CDMO & CMC/filing services,
    CODEXIS, INC.United StatesPublic CompanyBiopharma process enzymes and custom engineering (CodeEvolver-based),ECO Synthesis and nucleic acid manufacturing solutions,Other life science and industrial enzyme applications,
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx instruments and related consumables,ExPERT STx instruments and related consumables,ExPERT GTx instruments and related consumables,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO),Healthcare (oncology, neurology, fertility, rare diseases),Electronics (semiconductor and display materials, delivery equipment),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and bioproduction),Life Sciences (research and analytical instruments, genomics),Diagnostics (clinical instruments and consumables),
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical solutions (BLI, cytometry screening, PAT, live-cell imaging, SPR),Lab products and services (filtration, purification, lab water, weighing, pipettes, microbiological testing),
    GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
    TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments and cellular analysis devices,In vitro diagnostics (including COVID-19),
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Reagents,Other / Software and Services,
    QIAGENNetherlandsPublic CompanySample technologies (extraction and purification consumables/instruments),PCR and enzymes (qPCR/dPCR instruments and reagents),Molecular diagnostic assays (TB, oncology, sexual and reproductive health, transplant/viral load),
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, hardware, equipment),Display glass substrates (LCD/OLED),Specialty materials and mobile consumer electronics glass,
    LONZASwitzerlandPublic CompanyIntegrated Biologics (mammalian and drug product CDMO),Advanced Synthesis (small molecules, HPAPIs, ADCs, bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
    FUJIFILM HOLDINGS CORPORATIONJapanPublic CompanyHealthcare (medical systems, CDMO, pharma, regenerative, cosmetics/supplements),Electronics (display, semiconductor, image sensors, functional films, storage),Business Innovation (office equipment, document services, graphic communications),
    SYNGENE INTERNATIONAL LIMITEDIndiaPublic CompanyDiscovery Services (chemistry, biology, computational),Development Services (preclinical, CMC, clinical development),Biologics and Specialty Modalities,
    LGC LIMITEDSouth KoreaPublic CompanyEthylene-based synthetic resins (PE, EVA, LLDPE, UNIQABLE),Styrene-based resins (ABS, ASA, PS, EPS, SAN),Polycarbonate and engineering plastics (LUMID/LUXY, LUMILOY, LUPOL, LUPOY, etc.),

    PATHEON INC

    Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the life sciences sector.

    NANOSTRING TECHNOLOGIES, INC

    NanoString Technologies, Inc is a United States-based private company founded in 2003 with 550 employees specializing in life sciences technology.

    BIOGEN

    Biogen is a United States-based public company founded in 1978 with 7,500 employees engaged in biotechnology and pharmaceutical development.

    SIGMA-ALDRICH CORPORATION

    Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees providing life sciences products and services.

    VIVA BIOTECH LTD

    Viva Biotech Ltd is a China-based public company founded in 2008 with 2,169 employees providing drug discovery and development services.

    CODEXIS, INC.

    Codexis, Inc is a United States-based public company founded in 2002 with 146 employees focused on enzyme engineering and biocatalysis.

    MAXCYTE, INC

    MaxCyte, Inc is a United States-based public company founded in 1998 with 91 employees specializing in cell engineering technology.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc is a United States-based public company founded in 1956 with 125,000 employees serving the life sciences and laboratory sectors globally.

    MERCK KGAA

    Merck KGaA is a Germany-based public company founded in 1668 with 59,077 employees operating as a diversified pharmaceutical and chemical company.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees engaged in life sciences, diagnostics, and environmental solutions.

    AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.

    SARTORIUS AG

    Sartorius AG is a Germany-based public company founded in 1870 with 14,242 employees specializing in laboratory and bioprocess equipment.

    GENSCRIPT

    GenScript is a Hong Kong-based public company founded in 2002 with 6,165 employees providing biotechnology research services and products.

    TAKARA BIO INC.

    Takara Bio Inc is a Japan-based private company founded in 2002 with 1,779 employees specializing in biotechnology research tools and services.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc is a United States-based public company founded in 1952 with 7,450 employees manufacturing life sciences research and clinical diagnostics products.

    QIAGEN

    Qiagen is a Netherlands-based public company founded in 1984 with 5,500 employees providing molecular diagnostics and life sciences research solutions.

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a United States-based public company founded in 1947 with 19,000 employees providing preclinical and clinical laboratory services.

    CORNING INCORPORATED

    Corning Incorporated is a United States-based public company founded in 1851 with 67,200 employees manufacturing specialty glass and materials for life sciences applications.

    LONZA

    Lonza is a Switzerland-based public company founded in 1897 with 20,000 employees providing pharmaceutical and biotechnology manufacturing services.

    FUJIFILM HOLDINGS CORPORATION

    Fujifilm Holdings Corporation is a Japan-based public company founded in 1934 with 73,526 employees operating across imaging, pharmaceuticals, and life sciences sectors.

    SYNGENE INTERNATIONAL LIMITED

    Syngene International Limited is an India-based public company founded in 1993 with 6,692 employees providing drug discovery and development services.

    LGC LIMITED

    LGC Limited is a South Korea-based public company founded in 1947 with 14,019 employees operating in life sciences and analytical testing services.

    Reasons to Buy this Report

    • Market-Specific Growth Projections : Access detailed forecasts showing Japan's protein expression market expanding from USD 212.6M to USD 330.1M by 2031, enabling precise investment and expansion planning tailored to the Japanese market.
    • Competitive Landscape Intelligence : Understand key players, market share distribution, and competitive dynamics specific to Japan's protein expression sector, helping identify partnership and acquisition opportunities in this high-growth market.
    • Regulatory and Infrastructure Insights : Gain comprehensive knowledge of Japan's biotechnology infrastructure, regulatory environment, and R&D investment trends essential for market entry and operational success in the country.
    • Segment and Application Analysis : Identify high-demand protein expression applications and technologies within Japan, including monoclonal antibodies, biosimilars, and therapeutic proteins, to optimize product development strategies.
    • Strategic Market Positioning : Leverage Japan-specific market data to benchmark performance, identify growth gaps, and develop targeted go-to-market strategies for pharmaceutical, biotech, and research organizations operating in Japan.

    Frequently asked questions

    What is the current size of Japan's protein expression market?

    Japan's protein expression market is valued at USD 212.6 million in 2026 and is projected to reach USD 330.1 million by 2031.

    What is the growth rate of Japan's protein expression market?

    Japan's protein expression market is growing at a compound annual growth rate (CAGR) of 9.2% from 2026 to 2031.

    What factors are driving growth in Japan's protein expression market?

    Growth in Japan's protein expression market is driven by advanced biotech infrastructure, strong pharmaceutical R&D investments, government life sciences initiatives, and increasing demand for therapeutic biologics and recombinant proteins.

    Which expression systems are gaining adoption in Japan?

    Japan is seeing accelerated adoption of mammalian and cell-free protein expression systems, driven by demand for complex protein therapeutics and vaccine development platforms.

    How does Japan's market growth compare to global trends?

    Japan's 9.2% CAGR outpaces the global protein expression market CAGR of 8.3%, reflecting stronger regional demand and investment in biologics development.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the protein expression market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology,. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global protein expression market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Protein Expression Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the protein expression market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Protein Expression Market : Top-Down and Bottom-Up Approach

    Protein Expression Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

    Market Definition

    The protein expression market encompasses the technologies, products, and services required for protein production and analysis. This market includes various expression systems (mammalian, bacterial, yeast, algal, insect, and cell-free), reagents and instruments for transfection and cloning, growth reagents for cell culture during translation, and reagents and kits for downstream processes such as purification and characterization. It serves industries such as pharmaceuticals, biotechnology, academic & research institutes, CROs & CDMOs, and other industrial users, supporting applications in drug discovery, therapeutic development, and biochemical research, as well as other industries such as food and beverages, cosmetics, and textiles, among others.

    Key Stakeholders

    • Protein Expression Instrument & Reagent Manufacturers
    • Suppliers of Expression Systems
    • National and regional research boards and organizations
    • Research & development companies
    • Clinical research organizations (CROs)
    • Contract Manufacturing Organizations (CMOs)
    • Biotechnology companies
    • Research laboratories & academic institutes
    • Market research & consulting firms
    • Regulatory bodies

    Report Objectives

    • To define, describe, and forecast the protein expression market by offering, type, workflow, scale of operation, protein modality, application, product end user, service end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall protein expression market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia, United Arab Emirates, and the Rest of GCC) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market shares and core competencies
    • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Customization Options

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe protein expression market, by country
    • Further breakdown of the Rest of Asia Pacific protein expression market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

    Get the Full Protein Expression Market Report

    Full forecast, segment splits, and company analysis for all Protein Expression Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status